Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02649673
Title LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC

lung small cell carcinoma

ovarian cancer

fallopian tube cancer

peritoneum cancer


LCL161 + Topotecan

Age Groups: adult
Covered Countries USA

No variant requirements are available.